Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $51.52, for a total transaction of $51,520.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of NASDAQ:TRHC opened at $53.43 on Monday. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare Inc has a 1-year low of $40.86 and a 1-year high of $91.16. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 157.15 and a beta of 1.69.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. The business had revenue of $60.96 million for the quarter, compared to analysts’ expectations of $59.24 million. As a group, sell-side analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 earnings per share for the current year.

TRHC has been the subject of several research reports. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Thursday, May 30th. Piper Jaffray Companies lifted their price target on shares of Tabula Rasa HealthCare from $73.00 to $78.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. BidaskClub downgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Guggenheim initiated coverage on shares of Tabula Rasa HealthCare in a research report on Wednesday, April 17th. They issued a “neutral” rating and a $58.00 price target for the company. Finally, TheStreet downgraded shares of Tabula Rasa HealthCare from a “c-” rating to a “d+” rating in a research report on Tuesday, June 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and an average price target of $82.12.

A number of large investors have recently modified their holdings of TRHC. Rhumbline Advisers raised its stake in Tabula Rasa HealthCare by 24.1% during the fourth quarter. Rhumbline Advisers now owns 49,007 shares of the company’s stock worth $3,125,000 after acquiring an additional 9,502 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Tabula Rasa HealthCare by 12.9% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,704 shares of the company’s stock worth $491,000 after acquiring an additional 882 shares during the period. Comerica Bank raised its stake in Tabula Rasa HealthCare by 1.4% during the fourth quarter. Comerica Bank now owns 16,519 shares of the company’s stock worth $934,000 after acquiring an additional 235 shares during the period. Oregon Public Employees Retirement Fund acquired a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $412,000. Finally, Virginia Retirement Systems ET AL raised its stake in Tabula Rasa HealthCare by 22.2% during the fourth quarter. Virginia Retirement Systems ET AL now owns 5,500 shares of the company’s stock worth $351,000 after acquiring an additional 1,000 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Recommended Story: What are benefits of a growth and income fund?

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.